Simplex Trading’s MoonLake Immunotherapeutics MLTX Stock Holding History

Simplex Trading’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$630K	Buy	33,800 +700	+2%	+$11.6K	﹤0.01%	3006
2025 Q4	$436K	Sell	33,100 -172,400	-84%	-$2.03M	﹤0.01%	3427
2025 Q3	$1.47M	Buy	205,500 +182,000	+774%	+$9.49M	﹤0.01%	2637
2025 Q2	$1.11M	Buy	+23,500	New	+$957K	﹤0.01%	2674
2024 Q3	–	Sell	-4,200	Closed	-$184K	–	9149
2024 Q2	$184K	Sell	4,200 -11,500	-73%	-$487K	﹤0.01%	4739
2024 Q1	$788K	Sell	15,700 -53,500	-77%	-$2.9M	﹤0.01%	3369
2023 Q4	$4.18M	Buy	69,200 +54,100	+358%	+$2.79M	﹤0.01%	1717
2023 Q3	$860K	Buy	+15,100	New	+$834K	﹤0.01%	2827

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Simplex Trading's MLTX Position: Q1 2026 in Review

Simplex Trading reduced its MoonLake Immunotherapeutics (MLTX) stake by 89% in Q1 2026, selling an estimated $429K and leaving 3,075 shares worth $57.3K. The position accounts for ﹤0.01% of the portfolio, ranked #5719.

Simplex Trading first reported a position in MLTX in Q4 2023 and has held it in 5 quarters since. The position peaked at $2.12M in Q4 2023. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Simplex Trading held 3,075 shares of MoonLake Immunotherapeutics worth $57.3K as of Q1 2026.
Simplex Trading sold 25,897 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $429K.
MoonLake Immunotherapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #5719 holding.
Simplex Trading first reported a position in MoonLake Immunotherapeutics in Q4 2023 and has held it in 5 quarters since.
Simplex Trading's MoonLake Immunotherapeutics position peaked at $2.12M in Q4 2023.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.